[Compatibility of antihuman lymphocyte globulin (AHLG). Possible side effects and complications].
The results in the antihuman lymphocytic globulines (AHLG) therapy of 25 patients with predominantly haematological and neurological diseases are reported. Extent and scope of the side-effects observed are discussed. A careful clinical, clinico-chemical and immunological observation of the patients during the AHLG therapy is indispensable for performing this biological immunosuppression and a strict selection of patients is also required. Under these conditions there are no higher risk and responsibility in an AHLG therapy than in other intensive kinds of therapy.
D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D006505:Hepatitis / Q000628:therapy; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000628:therapy; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008199:Lymphadenitis / Q000628:therapy; D009103:Multiple Sclerosis / Q000628:therapy; D011234:Precipitins / Q000032:analysis; D012713:Serum Sickness / Q000209:etiology*
D000961:Antilymphocyte Serum; D011234:Precipitins
Zur Verträglichkeit von Antihumanlymphozytenglobulin (AHLG). Mögliche Nebenwirkungen und Komplikationen.